Fiserv, Inc. (FISV) is up 4.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The day’s move does not appear tied to a single, clearly identifiable headline, but it likely reflects renewed positioning after recent attention on the company’s governance agenda and ahead of its next major investor-facing update. A steady flow of strategic partnership announcements in 2026 may also be helping sentiment stabilize following last year’s sharp guidance reset.
Details:
Sources:
Fiserv Investor Relations, MarketScreener, Fintech Global, Simply Wall St
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$FISV Insider Trading Activity
$FISV insiders have traded $FISV stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FISV stock by insiders over the last 6 months:
- PAUL M TODD (Chief Financial Officer) purchased 17,000 shares for an estimated $1,060,970
- ADAM L. ROSMAN (Chief Admin. and Legal Officer) purchased 7,900 shares for an estimated $499,201
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FISV Hedge Fund Activity
We have seen 562 institutional investors add shares of $FISV stock to their portfolio, and 1,172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 20,936,453 shares (-81.2%) from their portfolio in Q4 2025, for an estimated $1,406,301,548
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 11,917,063 shares (-70.4%) from their portfolio in Q4 2025, for an estimated $800,469,121
- BANK OF AMERICA CORP /DE/ added 11,707,487 shares (+711.7%) to their portfolio in Q4 2025, for an estimated $786,391,901
- DODGE & COX added 10,840,613 shares (+28.1%) to their portfolio in Q4 2025, for an estimated $728,163,975
- HARRIS ASSOCIATES L P added 8,790,629 shares (+130.0%) to their portfolio in Q4 2025, for an estimated $590,466,549
- AMUNDI added 8,227,144 shares (+202.3%) to their portfolio in Q4 2025, for an estimated $552,617,262
- FEDERATED HERMES, INC. added 4,372,450 shares (+51127.8%) to their portfolio in Q4 2025, for an estimated $293,697,466
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FISV Congressional Stock Trading
Members of Congress have traded $FISV stock 8 times in the past 6 months. Of those trades, 4 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $FISV stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 5 times. They made 4 purchases worth up to $60,000 on 03/13, 12/19, 11/18, 11/12 and 1 sale worth up to $15,000 on 02/10.
- SENATOR JOHN BOOZMAN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 01/29, 11/21.
- REPRESENTATIVE THOMAS H. KEAN, JR. sold up to $15,000 on 10/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$FISV Price Targets
Multiple analysts have issued price targets for $FISV recently. We have seen 11 analysts offer price targets for $FISV in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Will Nance from Goldman Sachs set a target price of $70.0 on 04/14/2026
- Bryan Keane from Citigroup set a target price of $60.0 on 04/09/2026
- Dominick Gabriele from Loop Capital set a target price of $62.0 on 03/31/2026
- Jason Kupferberg from Wells Fargo set a target price of $62.0 on 03/27/2026
- Ramsey El-Assal from Cantor Fitzgerald set a target price of $70.0 on 03/11/2026
- Ivan Feinseth from Tigress Financial set a target price of $95.0 on 03/11/2026
- Matthew Coad from Truist Securities set a target price of $65.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.